Lantheus (NASDAQ:LNTH) updated its fourth quarter 2021 earnings guidance on Thursday. The company provided earnings per share guidance of $0.150-$0.180 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.160. The company issued revenue guidance of $110 million-$115 million, compared to the consensus revenue estimate of $106.03 million.Lantheus also updated its FY 2021 guidance to $0.400-$0.430 EPS.
A number of research firms recently weighed in on LNTH. Zacks Investment Research downgraded Lantheus from a buy rating to a hold rating in a research note on Saturday, November 13th. SVB Leerink restated an outperform rating on shares of Lantheus in a research note on Friday, October 22nd.
LNTH traded down $0.22 during trading on Thursday, reaching $28.38. 316,142 shares of the stock were exchanged, compared to its average volume of 557,613. The business’s 50 day moving average price is $25.91 and its two-hundred day moving average price is $25.41. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.62 and a quick ratio of 2.18. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -55.65, a P/E/G ratio of 3.13 and a beta of 1.34. Lantheus has a 1 year low of $12.89 and a 1 year high of $31.60.
In other news, CEO Mary Anne Heino sold 13,333 shares of the company’s stock in a transaction on Wednesday, November 10th. The stock was sold at an average price of $30.12, for a total value of $401,589.96. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Andrea Sabens sold 1,242 shares of the company’s stock in a transaction on Monday, November 15th. The shares were sold at an average price of $30.47, for a total value of $37,843.74. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,683 shares of company stock worth $626,113. 1.40% of the stock is owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in LNTH. Wells Fargo & Company MN increased its stake in Lantheus by 79.5% in the second quarter. Wells Fargo & Company MN now owns 63,953 shares of the medical equipment provider’s stock valued at $1,767,000 after purchasing an additional 28,329 shares during the last quarter. Morgan Stanley increased its stake in Lantheus by 49.0% in the second quarter. Morgan Stanley now owns 255,027 shares of the medical equipment provider’s stock valued at $7,050,000 after purchasing an additional 83,817 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in Lantheus by 162.0% in the third quarter. Cubist Systematic Strategies LLC now owns 6,563 shares of the medical equipment provider’s stock valued at $169,000 after purchasing an additional 4,058 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Lantheus by 0.4% in the third quarter. Bank of New York Mellon Corp now owns 620,082 shares of the medical equipment provider’s stock valued at $15,923,000 after purchasing an additional 2,339 shares during the last quarter. Hedge funds and other institutional investors own 94.46% of the company’s stock.
Lantheus Company Profile
Lantheus Holdings, Inc engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes, and assist clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments.
See Also: What is Put Option Volume?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.